Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acknowledge, acknowledged, aforementioned, Alexion, BLA, borne, briefly, campaign, ceiling, celebrate, cemdomespib, charitable, CHMP, contextualized, culminated, database, deficiency, deploy, device, dispensed, DNA, durability, dysregulated, dysregulation, editorial, Eloxx, emphasized, enrichment, enrollee, ERC, ESPP, exempt, explanation, FDORA, feedback, ferritin, FTL, FXN, gait, gift, glutamyl, heavy, hypothetical, Icahn, IRA, KemPharm, Lava, Lexeo, liaison, light, longest, mechanistic, middle, Minnie, Mount, neurostimulation, opposed, Pantry, payer, penalize, pharmacovigilance, PhRMA, pregnancy, Proclaim, prognostic, propensity, proportionately, Rallybio, reiterated, retention, River, Ryder, SCS, Secretary, Sinai, situation, slower, Steven, stipulation, subsidize, tactical, tertiary, thereunder, traditional, unjust, untreated, upstream, vehicle, withdrew, XR
Removed:
abridge, Akebia, Alliance, autoimmune, billion, Century, consultancy, Convention, Copenhagen, declined, deduction, Denmark, differentiating, discriminate, doubled, Dystrophy, educate, encourage, enzyme, existed, faced, FASB, fibrotic, focal, Francisco, injectable, Jack, kidneycode, lademirsen, linked, liquid, lixivaptan, lt, mg, mice, Muscular, nephropathy, Nielsen, Orphazyme, Palladio, PHOENIX, Pioneer, practical, proposal, ratable, ratio, reacquire, reauthorized, receptor, reclassified, remained, San, segmental, spent, spinocerebellar, suggested, sunset, supported, transient, unchanged, unfold, urinary
Filing tables
Filing exhibits
RETA similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Reata Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Manmeet S. Soni, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: February 24, 2023 |
| By: |
| /s/ Manmeet S. Soni |
|
|
|
| Manmeet S. Soni |
|
|
|
| Chief Operating Officer, Chief Financial Officer, and President |
|
|
|
| (Principal Financial Officer) |